NovoCure (NVCR) Cash from Financing Activities (2014 - 2026)

NovoCure's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at -$166000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 103.16% year-over-year to -$166000.0; the TTM figure through Mar 2026 stood at -$456.8 million (down 579.04% YoY), while the FY2025 annual figure was -$451.3 million, down 599.74% from the prior year.
• Cash from Financing Activities came in at -$166000.0 for Q1 2026 at NovoCure, up from -$559.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $100.5 million in Q3 2025 to a low of -$559.5 million in Q4 2025.
• A 5-year average of -$19.4 million and a median of $3.1 million in 2022 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 100417.0% in 2025 and fell as far as 20937.77% in 2025.
• NovoCure's Cash from Financing Activities stood at $3.4 million in 2022, then sank by 43.99% to $1.9 million in 2023, then jumped by 40.58% to $2.7 million in 2024, then plunged by 20937.77% to -$559.5 million in 2025, then jumped by 99.97% to -$166000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$166000.0, -$559.5 million, and $100.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison